口炎粉通过增加Col11a1表达来改善口腔的症状
Mianjie Wang1, Yulin Wang2, Wukai Ma3
1Department of Stomatology, The Second Affiliated Hospital of Guizhou University of Traditional Chinese Medicine, Guiyang, Guizhou, 550001, China.
Combinatorial chemistry & high throughput screening
|March 14, 2026
概括
口腔炎粉末通过调节Col11a1等关键基因,减少纤维化和加速伤口愈合,有效治疗口腔. 这项研究使用RNA测序和生物信息学阐明了它的药理机制.
科学领域:
- 药理学 药理学是指药理学的学科.
- 基因组学就是基因组学.
- 传统中国医药 传统中国医药
背景情况:
- 口炎粉是一种用于治疗口腔的传统中医药 (TCM).
- 它的治疗机制尚不清楚.
- 本研究旨在澄清口腔炎粉末用于OU治疗的药理基础.
研究的目的:
- 调查口腔炎粉在治疗口腔的药理机制.
- 为了确定关键的基因和途径,涉及口腔炎粉末的治疗作用.
- 为口腔炎粉末的临床应用提供科学理由.
主要方法:
- 在治疗口腔炎粉末之前和之后,对口腔粘膜组织进行了RNA测序.
- 差异表达基因 (DEGs) 被确定并与与疼痛相关的基因交叉.
- 蛋白与蛋白相互作用 (PPI) 网络分析被用来识别关键基因,随后在口腔鼠模型中进行验证.
主要成果:
- 443个DEG被确定,在与疼痛相关的基因交叉后产生了20个候选基因.
- 通过PPI网络分析确定了四个关键基因 (Col11a1,Col5a1,Enpp1,Pth1r).
- 在口腔鼠模型中,口腔炎粉末上调了Col11a1,缓解了纤维化,并加速了伤口愈合.
结论:
- 这项研究确定了Col11a1作为口腔上口腔炎粉末治疗效果的关键基因.
- 现代药理技术证实了口腔炎粉在治疗口腔的有效性.
- 这些发现为在临床实践中使用口炎粉提供了科学依据.
相关概念视频
Drugs for Treatment of Ulcerative Colitis in IBD
591
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
591
Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents
1.9K
In the intricate landscape of the gastric lumen, excessive acid secretion disrupts the natural defense mechanisms, weakening the mucus-bicarbonate barrier. This vulnerability allows pepsin to infiltrate epithelial cells, digesting mucosal proteins and triggering erosion, leading to ulcer formation.
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
1.9K
Peptic Ulcer Disease II: Pathophysiology
2.4K
Peptic Ulcer Disease (PUD) is characterized by the development of ulcers in the stomach or duodenal mucosa. Its pathophysiology is complex, involving a balance between damaging and protective elements.
Damaging agents such as Helicobacter pylori, gastric acid, pepsin, and nonsteroidal anti-inflammatory drugs (NSAIDs) can weaken the mucosal defense, allowing hydrogen ions to infiltrate back and harm epithelial cells.
Damaging agents such as Helicobacter pylori, gastric acid, pepsin, and nonsteroidal anti-inflammatory drugs (NSAIDs) can weaken the mucosal defense, allowing hydrogen ions to infiltrate back and harm epithelial cells.
2.4K
Peptic Ulcer Disease IV: Management
607
Medical treatment strategies for peptic ulcers encompass various methods. The primary goal of treatment is to diminish gastric acidity and strengthen mucosal defense mechanisms.
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
607
Peptic Ulcer Disease I: Introduction
981
Peptic Ulcer Disease (PUD) is characterized by mucosal excavation in the esophagus, stomach, pylorus, or duodenum. It can manifest as acute or chronic based on the extent and duration of mucosal involvement.
An acute ulcer, marked by superficial erosion and minimal inflammation, swiftly resolves upon identifying and addressing the underlying cause. In contrast, a chronic ulcer persists, potentially eroding through the muscular wall and forming fibrous tissue.
Peptic ulcers can also be...
An acute ulcer, marked by superficial erosion and minimal inflammation, swiftly resolves upon identifying and addressing the underlying cause. In contrast, a chronic ulcer persists, potentially eroding through the muscular wall and forming fibrous tissue.
Peptic ulcers can also be...
981
Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents
1.4K
The gastric mucosa produces prostaglandins E2 (PGE2) and prostacyclin (PGI2), crucial in maintaining gastric health. They exert cytoprotective effects, including increasing bicarbonate secretion, releasing protective mucin, reducing gastric acid output, and preventing harmful vasoconstriction. These effects are mediated through various receptors, such as EP1, EP2, EP3, and EP4.
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
1.4K


